Hydroxyurea in Sickle Cell Disease: Drug Review

被引：154

作者：

Agrawal, Rohit Kumar ^{[1
]}

Patel, Rakesh Kantilal ^{[1
]}

Shah, Varsha ^{[1
]}

Nainiwal, Lalit ^{[1
]}

Trivedi, Bhadra ^{[1
]}

机构：

[1] Dhiraj Gen Hosp, Vadodara, Gujarat, India

来源：

INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION | 2014年 / 30卷 / 02期

关键词：

Hydroxyurea; HbF level; Neutropenia; CHILDREN; ANEMIA; MODULATION; MORTALITY; THERAPY;

D O I：

10.1007/s12288-013-0261-4

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Hydroxyurea, a myelosuppressive agent, is the only effective drug proven to reduce the frequency of painful episodes. It raises the level of HbF and the haemoglobin level. It usually decreases the rate of painful episodes by 50 %. It was first tested in sickle cell disease in 1984. It also decreases the rate of ACS episodes and blood transfusions by similar to 50 % in adults. It was developed as an anticancer drug and has been used to treat myeloproliferative syndromes-leukemia, melanoma, and ovarian cancer. It was approved for use by FDA in adults. Side effects includes neutropenia, bone marrow suppression, elevation of hepatic enzymes, anorexia, nausea, vomiting and infertility.

引用

收藏

页码：91 / 96

页数：6

相关论文

共 24 条

[1]

Exposure to Hydroxyurea and Pregnancy Outcomes in Patients With Sickle Cell Anemia [J].

Ballas, Samir K. ;

McCarthy, William F. ;

Guo, Nan ;

DeCastro, Laura ;

Bellevue, Rita ;

Barton, Bruce A. ;

Waclawiw, Myron A. .

JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2009, 101 (10) :1046-1051

[2]

National institutes of health consensus development conference statement: Hydroxyurea treatment for sickle cell disease [J].

Brawley, Otis W. ;

Cornelius, Llewellyn J. ;

Edwards, Linda R. ;

Gamble, Vanessa Northington ;

Green, Bettye L. ;

Inturrisi, Charles ;

James, Andra H. ;

Laraque, Danielle ;

Mendez, Magda ;

Montoya, Carolyn J. ;

Pollock, Brad H. ;

Robinson, Lawrence ;

Scholnik, Aaron P. ;

Schori, Melissa .

ANNALS OF INTERNAL MEDICINE, 2008, 148 (12) :932-+

[3]

CHARACHE S, 1992, BLOOD, V79, P2555

[4]

de Montalembert M, 2006, HAEMATOLOGICA, V91, P125

[5]

Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease [J].

deMontalembert, M ;

Belloy, M ;

Bernaudin, F ;

Gouraud, F ;

Capdeville, R ;

Mardini, R ;

Philippe, N ;

Jais, JP ;

Bardakdjian, J ;

Ducrocq, R ;

MaierRedelsperger, M ;

Elion, J ;

Labie, D ;

Girot, R .

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1997, 19 (04) :313-318

[6]

Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease [J].

Gladwin, MT ;

Shelhamer, JH ;

Ognibene, FP ;

Pease-Fye, ME ;

Nichols, JS ;

Link, B ;

Patel, DB ;

Jankowski, MA ;

Pannell, LK ;

Schechter, AN ;

Rodgers, GP .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 116 (02) :436-444

[7]

Pharmacotherapy in sickle cell disease - state of the art and future prospects [J].

Hankins, Jane ;

Aygun, Banu .

BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 (03) :296-308

[8]

Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study [J].

Hankins, JS ;

Ware, RE ;

Rogers, ZR ;

Wynn, LW ;

Lane, PA ;

Scott, JP ;

Wang, WC .

BLOOD, 2005, 106 (07) :2269-2275

[9]

Hydroxyurea for children with sickle cell disease [J].

Heeney, Matthew M. ;

Ware, Russell E. .

PEDIATRIC CLINICS OF NORTH AMERICA, 2008, 55 (02) :483-+

[10]

Chemical and functional analysis of hydroxyurea oral solutions [J].

Heeney, MM ;

Whorton, MR ;

Howard, TA ;

Johnson, CA ;

Ware, RE .

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2004, 26 (03) :179-184